BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 3638964)

  • 1. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.
    Pangburn MK; Müller-Eberhard HJ
    Biochem J; 1986 May; 235(3):723-30. PubMed ID: 3638964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
    Pryzdial EL; Isenman DE
    J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C3 convertase of the alternative complement pathway. Demonstration of an active, stable C3b, Bb (Ni) complex.
    Fishelson Z; Pangburn MK; Müller-Eberhard HJ
    J Biol Chem; 1983 Jun; 258(12):7411-5. PubMed ID: 6553050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The C3/C5 convertase of the alternative pathway of complement: stabilization and restriction of control by lanthanide ions.
    Fishelson Z; Müller-Eberhard HJ
    Mol Immunol; 1983 Mar; 20(3):309-15. PubMed ID: 6553181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme.
    Rawal N; Pangburn MK
    J Biol Chem; 1998 Jul; 273(27):16828-35. PubMed ID: 9642242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
    Waldo FB; Forristal J; Beischel L; West CD
    J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
    Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
    J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3 convertase of the human alternative pathway of complement: modulation of enzyme activity and stability by mouse monoclonal antibodies to Bb.
    Fishelson Z; Müller-Eberhard HJ
    Eur J Immunol; 1987 Feb; 17(2):303-4. PubMed ID: 3644748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the initial C3 convertase of the alternative pathway of human complement.
    Fishelson Z; Pangburn MK; Müller-Eberhard HJ
    J Immunol; 1984 Mar; 132(3):1430-4. PubMed ID: 6559201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.
    DiScipio RG
    Biochem J; 1981 Dec; 199(3):497-504. PubMed ID: 6918218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    Parker CJ; Baker PJ; Rosse WF
    J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3.
    Pangburn MK; Müller-Eberhard HJ
    Ann N Y Acad Sci; 1983; 421():291-8. PubMed ID: 6586103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1982 Dec; 129(6):2603-7. PubMed ID: 6923908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
    Fearon DT
    Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1971-5. PubMed ID: 273923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on C3 convertases. Inhibition of C5 convertase formation by peptides containing aromatic amino acids.
    Kossorotow A; Opitz W; Etschenberg E; Hadding U
    Biochem J; 1977 Nov; 167(2):377-82. PubMed ID: 597250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.